We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Successful treatment of acquired reactive perforating collagenosis with itraconazole.
European Journal of Medical Research 2021 July 14
BACKGROUND: Acquired reactive perforating collagenosis (ARPC) is a rare form of transepithelial elimination in which altered collagen is extruded through the epidermis.
CASE PRESENTATION: A 23-year-old male presented with cup-like ulcerated lesions on his limbs since 3 months. A series of serological and immunological tests showed no abnormalities. A diagnosis of ARPC was based on skin biopsy findings. The patient was cured using treatment with itraconazole for 8 weeks, in the absence of a fungal infection.
CONCLUSIONS: The anti-inflammatory and anti-angiogenic effects of itraconazole can have good therapeutic benefits for ARPC.
CASE PRESENTATION: A 23-year-old male presented with cup-like ulcerated lesions on his limbs since 3 months. A series of serological and immunological tests showed no abnormalities. A diagnosis of ARPC was based on skin biopsy findings. The patient was cured using treatment with itraconazole for 8 weeks, in the absence of a fungal infection.
CONCLUSIONS: The anti-inflammatory and anti-angiogenic effects of itraconazole can have good therapeutic benefits for ARPC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app